Mobile

A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients + Pharmacogenetics Blood Sample Amendment Number 01 - ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-005099-33

A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 1.0, dated 30-Mar-06, and Pharmacogenomics Tissue Sample Amendment Number 02 - Site Specific, version 1.0, dated 12-Apr-06

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess efficacy of BMS-275183 in pretreated NSCLC patients as measured by the tumor response rate according to the SWOG criteria.

Critère d'inclusion

  • Patients with pretreated locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC)

Liens